Clinical trials: Types, design, and end-points

Current Opinion in Rheumatology

Volumn 13, Issue 6, 2001, Pages 512-515

  Seibold, James R ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; CLINICAL RESEARCH; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME;

CLINICAL TRIALS; GOALS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME;

EID: 0035161188     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200111000-00011     Document Type: Review

References (18)

1. Guidelines for clinical trials in systemic sclerosis (scleroderma) 1. Disease-modifying interventions
2. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)
3. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis
4. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis. Analysis of a two-year, double-blind, randomized, controlled clinical trial
5. Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial
6. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis
7. Scleroderma
8. Inter and intra-observer variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis
9. Is skin involvement a relevant outcome measure in clinical trials of systemic sclerosis?
10. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose vs low-dose penicillamine in systemic sclerosis trial
11. Skin thickness score is a predictor and correlate of outcome: The high-dose vs low-dose penicillamine trial
12. Recombinant human relaxin in the treatment of scleroderma: A randomized, double-blind, placebo-controlled multicenter trial
13. A randomized controlled trial of methotrexate versus placebo in early diffuse scleroderma
14. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres
15. European multicentre study to define activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity inexes
16. U.S. Phase III trial of relaxin in diffuse scleroderma
17. Oral Iloprost in patients with Raynaud phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study
18. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on disease